Filing Flows › Usana Health Sciences (USNA) › Q4 2024
Usana Health Sciences (USNA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 12, 2025
Usana Health Sciences (USNA) reported revenue of $214M for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and +7% from the quarter before. Operating margin was 3.8%, net earnings $4.5M (2.1% of revenue).
Usana Health Sciences, Q4 2024: revenue $214M (-3% year over year), operating margin 3.8%, net earnings $4.5M, operating cash flow $5.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $214M | +7% | -3% |
| Gross profit | $175M | +9% | -2% |
| Operating profit | $8.2M | -47% | -66% |
| Net earnings | $4.5M | -58% | -73% |
| Operating cash flow | $5.8M | -80% | -78% |
| Free cash flow | $4.0M | -85% | -79% |
What changed
Revenue was $213.6M in Q4 2024, down 3% year over year and up 7% from the previous quarter.
Gross margin was 82.0%, up 1.1 points from a year earlier. Operating profit was $8.2M, a 3.8% margin (down 7.1 points year over year). Operating expenses grew 8% against a revenue fall of 3%. The fastest-growing cost line was SG&A (+25%). Net earnings were $4.5M, down 73% year over year. The effective tax rate was 57.0%. Non-operating items added $2.2M, 21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $5.8M (down 78% year over year), 129% of net earnings. Non-cash charges added back $4.0M of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items used $6.3M. Capital expenditures of $1.8M left free cash flow of $4.0M.
Questions
What was Usana Health Sciences' revenue in the fourth quarter 2024?
Usana Health Sciences (USNA) reported revenue of $214M for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and +7% from the quarter before.
Was Usana Health Sciences profitable in the fourth quarter 2024?
Operating profit was $8.2M (3.8% of revenue) and net earnings $4.5M.